BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 204 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $644,000 | +198.1% | 4,426 | +142.8% | 0.00% | – |
| Q1 2022 | $216,000 | -86.6% | 1,823 | -90.3% | 0.00% | -100.0% |
| Q4 2020 | $1,609,000 | +54.9% | 18,776 | +17.4% | 0.00% | +100.0% |
| Q3 2020 | $1,039,000 | +602.0% | 15,992 | +267.0% | 0.00% | – |
| Q1 2020 | $148,000 | -80.7% | 4,357 | -76.3% | 0.00% | -100.0% |
| Q3 2019 | $766,000 | -67.9% | 18,374 | -66.2% | 0.00% | -71.4% |
| Q2 2019 | $2,383,000 | +27.1% | 54,434 | +49.3% | 0.01% | +40.0% |
| Q1 2019 | $1,875,000 | +591.9% | 36,448 | +396.7% | 0.01% | +400.0% |
| Q4 2018 | $271,000 | +72.6% | 7,338 | +75.3% | 0.00% | 0.0% |
| Q3 2018 | $157,000 | +35.3% | 4,186 | +41.7% | 0.00% | – |
| Q2 2018 | $116,000 | -80.3% | 2,954 | -87.1% | 0.00% | -100.0% |
| Q1 2018 | $588,000 | +818.8% | 22,855 | +849.9% | 0.03% | +766.7% |
| Q4 2017 | $64,000 | – | 2,406 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |